Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations
about
Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID)Use of the tumor necrosis factor-blockers for Crohn's diseaseUse of thiopurines in inflammatory bowel disease: Safety issues.Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk.Genetic and functional profiling of Crohn's disease: autophagy mechanism and susceptibility to infectious diseasesA common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopeniaThe long-term risk of continuous immunosuppression using thioguanides in inflammatory bowel diseaseMyelosuppression monitoring after immunomodulator initiation in veterans with inflammatory bowel disease: a national practice audit.Thiopurine therapy in inflammatory bowel disease.A case of therapy-related myeloid neoplasm in a patient with Crohn's disease treated with azathioprine.Pharmacogenetics in dermatology: a patient-centered update.The role of thiopurine metabolite monitoring in inflammatory bowel disease.Asia-Pacific consensus statements on Crohn's disease. Part 2: Management.Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.Toxicity and response to thiopurines in patients with inflammatory bowel disease.Azathioprine-associated myelodysplastic syndrome in two patients with ulcerative colitis.Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype.Optimizing therapy with 6-mercaptopurine and azathioprine: to measure or not to measure?Nucleoside diphosphate-linked moiety X-type motif 15 C415T variant as a predictor for thiopurine-induced toxicity in Indian patients.Influences of XDH genotype by gene-gene interactions with SUCLA2 for thiopurine-induced leukopenia in Korean patients with Crohn's disease.
P2860
Q26996946-3F98D672-B9FC-4DA4-A141-91FA1B19D68FQ27030762-74D467EA-F4D5-4102-98A5-316ACB6BBC7EQ33621267-88527750-248B-4266-9ECF-B5436378B696Q33905391-50133066-A6D3-4161-9BAA-5C78BAB39924Q34037058-AD149DB8-2B6E-4D00-AFFC-FE2836118D61Q34433052-ED2C36DA-5D54-4DE7-A533-CD85570DDCCBQ36443655-99CE6453-8FFB-4FFC-B340-2637DA30A221Q37721906-B23537A1-EBAD-4C3D-B18C-04164D7D24F4Q37798819-848FEB27-E92E-4F17-A498-55E125F762EDQ38008808-1E1E1905-99AD-4FA7-AA77-77D8B616C939Q38115822-C48E60E1-F4F0-461E-8696-310BB3F389A7Q38200692-7B3CF393-8F7A-4882-8D0E-46132791E7FDQ38394726-29E9B7B8-1BF6-412E-845D-164C22AF2B41Q38417177-10E8D92A-BEAE-4DE9-97B3-6A43F8C71D01Q38443981-E386363B-1A14-409F-AD48-B644EFF3DDF6Q38609110-C5770D0D-798C-43C8-9551-AD14A97C0E39Q40044141-D8522F3B-F4B7-42EF-8CF0-1016A78FE4DBQ41174990-B95BABED-595E-4848-8E92-357529036A4EQ51641578-476385A1-2687-4A5F-AA55-6DC5DC239EB8Q53262827-EFC05CD1-3A13-4919-8BE6-E21DD2AD6994
P2860
Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Timing of myelosuppression dur ...... for monitoring recommendations
@ast
Timing of myelosuppression dur ...... for monitoring recommendations
@en
type
label
Timing of myelosuppression dur ...... for monitoring recommendations
@ast
Timing of myelosuppression dur ...... for monitoring recommendations
@en
prefLabel
Timing of myelosuppression dur ...... for monitoring recommendations
@ast
Timing of myelosuppression dur ...... for monitoring recommendations
@en
P2093
P2860
P1476
Timing of myelosuppression dur ...... for monitoring recommendations
@en
P2093
Fernando S Velayos
James D Lewis
James E Alison
Laura M Asakura
Lisa J Herrinton
Monina Pascua
Oren Abramson
P2860
P304
1195-201; quiz 1141-2
P356
10.1016/J.CGH.2009.07.019
P407
P577
2009-07-22T00:00:00Z